Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 111 to 120 of 261 total matches.
Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
with female partners of reproductive
potential should use effective contraception during
treatment ...
The FDA has approved lutetium lu 177 vipivotide
tetraxetan (Pluvicto – Novartis) for treatment of
prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate
cancer (mCRPC) in adults previously treated with
androgen receptor (AR) pathway inhibitors and
taxane-based chemotherapy.
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
therapy and
oral contraceptives)
mexiletine
norfloxacin
ofloxacin
rucaparib
tacrine
thiabendazole ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Talazoparib (Talzenna) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
potential should use effective contraception during
treatment with talazoparib and for 4 months after ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor talazoparib (Talzenna – Pfizer) has been
approved by the FDA for use in combination with the
androgen receptor blocker enzalutamide (Xtandi) for
treatment of adults with homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant
prostate cancer (mCRPC). The drug has
been available since 2018 for treatment of deleterious
or suspected deleterious germline BRCA-mutated
(gBRCAm), HER2-negative locally advanced or
metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 doi:10.58347/tml.2023.1682e | Show Introduction Hide Introduction
Niraparib/Abiraterone Acetate (Akeega) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
potential should
use effective contraception during treatment with
niraparib/abiraterone acetate and for 4 ...
Akeega (Janssen), a fixed-dose combination of
the oral poly(ADP-ribose) polymerase (PARP)
inhibitor niraparib (Zejula) and the antiandrogen
abiraterone acetate (Zytiga, and others), has been
approved by the FDA for use in combination with
prednisone for treatment of adults with deleterious
or suspected deleterious BRCA-mutated (BRCAm)
metastatic castration-resistant prostate cancer
(mCRPC). Niraparib has been available since 2017
for treatment of epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Abiraterone acetate has
been available since 2011 for treatment of CRPC...
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e146-7 doi:10.58347/tml.2023.1684c | Show Introduction Hide Introduction
Cladribine (Mavenclad) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019 (Issue 1577)
. Women or men of
reproductive potential taking cladribine should use
effective contraception during ...
The FDA has approved cladribine (Mavenclad – EMD
Serono), a purine antimetabolite, for oral treatment
of adults with relapsing forms of multiple sclerosis
(MS), including relapsing-remitting disease and
active secondary progressive MS (SPMS), who
cannot tolerate or have had an inadequate response
to other drugs indicated for treatment of MS. It is
not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved
for treatment of hairy cell leukemia, has been
used off-label for treatment of MS.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
use effective contraception during treatment with fam-trastuzumab deruxtecan and for at least 7 months ...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
women should
generally be avoided
Women who could become
pregnant should use effective
contraception ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
of drugs
metabolized by these isozymes, including oral
contraceptives.
Use of mavacamten ...
The FDA has approved mavacamten (Camzyos –
MyoKardia/BMS), a modulator of cardiac myosin, to
improve functional capacity and symptoms in adults
with New York Heart Association (NYHA) class II or
III obstructive hypertrophic cardiomyopathy (HCM)
who have a baseline left ventricular ejection fraction
(LVEF) ≥55%. Mavacamten is the first drug in its class
to become available in the US.
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
contraception does not qualify for treatment
with the drug.
VULVOVAGINAL CANDIDIASIS — Vulvovaginal ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Drugs that Cause Photosensitivity
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995 (Issue 946)
(Atromid-S, and others)
Contraceptives, oral
Desoximetasone (Topicort, and others)
Disopyramide (Norpace ...
As the weather becomes warmer, physicians may see more photosensitivity reactions due to systemic or topical drugs, perfumes, cosmetics or sunscreens. Even brief exposure to sunlight in warm or cold weather can cause intense cutaneous reactions in patients with drug-induced photosensitivity, and some patients may continue to be sensitive to sunlight long after stopping use of the offending agent.